Skip to main content

Advertisement

SpringerLink
Log in

Fulvestrant plus targeted agents versus fulvestrant alone for treatment of hormone-receptor positive advanced breast cancer progressed on previous endocrine therapy: a meta-analysis of randomized controlled trials

  • Review Article
  • Published:
Breast Cancer Aims and scope Submit manuscript

Abstract

To compare the addition of targeted agents to fulvestrant with fulvestrant alone in hormone-receptor positive advanced breast cancer progressed on previous endocrine therapy; a meta-analysis of all relevant randomized controlled trials was performed. The PubMed, Embase databases and the Cochrane Central Register of Controlled Trials were searched for relevant publications reporting randomized controlled trials between January 2000 and June 2016. Progression-free survival (PFS), objective response rate (ORR), disease control rate (DCR), and toxicity were assessed. Eight trials with a total of 2,470 patients were included in this meta-analysis. Compared with fulvestrant alone, combination therapy improved PFS (HR = 0.79; 95% CI 0.72–0.87; P = 0.00), increased ORR (RR = 1.70; 95% CI 1.30–2.21; P = 0.00), and showed a trend of increase in DCR (RR = 1.27; 95% CI 0.96–1.69, P = 0.09). In network analysis, only CD4/6 and PI3K/m-TOR inhibitors showed significant treatment effects with a P-score of 0.9999 and 0.7615, respectively. Patients treated with combination therapy developed more grade 3 or greater toxic effects (RR = 1.24; 95% CI 1.13–1.36; P = 0.00). Combining targeted agents with fulvestrant showed benefit but with increased toxicity in patients with advanced breast cancer compared with fulvestrant alone. Biomarkers for treatment optimization are lacking. The CD4/6 and PI3K/m-TOR pathways merit further investigation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Yang XR, Chang-Claude J, Goode EL, Couch FJ, Nevanlinna H, et al. Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies. J Natl Cancer Inst. 2011;103:250–63.

    Article  PubMed  Google Scholar 

  2. Sini V, Cinieri S, Conte P, De Laurentiis M, Leo AD, et al. Endocrine therapy in post-menopausal women with metastatic breast cancer: from literature and guidelines to clinical practice. Crit Rev Oncol Hematol. 2016;100:57–68.

    Article  PubMed  Google Scholar 

  3. Bonneterre J, Buzdar A, Nabholtz JM, Robertson JF, Thürlimann B, et al. Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma. Cancer. 2001;92:2247–58.

    Article  CAS  PubMed  Google Scholar 

  4. Mouridsen H, Sun Y, Gershanovich M, Perez-Carrion R, Becquart D, et al. Superiority of letrozole to tamoxifen in the first-line treatment of advanced breast cancer: evidence from metastatic subgroups and a test of functional ability. Oncologist. 2004;9:489–96.

    Article  CAS  PubMed  Google Scholar 

  5. Chia S, Gradishar W, Mauriac L, Bines J, Amant F, et al. Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT. J Clin Oncol. 2008;26:1664–70.

    Article  CAS  PubMed  Google Scholar 

  6. Cope S, Ouwens MJNM, Jansen JP, Schmid P. Progression-free survival with fulvestrant 500 mg and alternative endocrine therapies as second-line treatment for advanced breast cancer: a network meta-analysis with parametric survival models. Value Health. 2013;16:403–17.

    Article  PubMed  Google Scholar 

  7. Di Leo A, Jerusalem G, Petruzelka L, Torres R, Bondarenko IN, et al. Results of the CONFIRM phase iii trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer. J Clin Oncol. 2010;28:4594–600.

    Article  PubMed  Google Scholar 

  8. Johnston SRD, Kilburn LS, Ellis P, Dodwell D, Cameron D, et al. Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trial. Lancet Oncol. 2013;14:989–98.

    Article  CAS  PubMed  Google Scholar 

  9. Baselga J, Campone M, Piccart M, Burris HA 3rd, Rugo HS, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med. 2012;366:520–9.

    Article  CAS  PubMed  Google Scholar 

  10. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17:1–12.

    Article  CAS  PubMed  Google Scholar 

  11. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007;8:16.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Bergh J, Jonsson PE, Lidbrink EK, Trudeau M, Eiermann W, et al. FACT: an open-label randomized phase III study of fulvestrant and anastrozole in combination compared with anastrozole alone as first-line therapy for patients with receptor-positive postmenopausal breast cancer. J Clin Oncol. 2012;30:1919–25.

    Article  CAS  PubMed  Google Scholar 

  13. Howell A, Robertson JFR, Abram P, Lichinitser MR, Elledge R, et al. Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial. J Clin Oncol. 2004;22:1605–13.

    Article  CAS  PubMed  Google Scholar 

  14. Johnston SRD, Kilburn LS, Ellis P, Dodwell D, Cameron D, et al. Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trial. Lancet Oncol. 2013;14:989–98.

    Article  CAS  PubMed  Google Scholar 

  15. Leo AD, Jerusalem G, Petruzelka L, Torres R, Bondarenko IN, et al. Final overall survival: fulvestrant 500 mg vs 250 mg in the randomized CONFIRM trial. J Natl Cancer Inst. 2013;106:djt337.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Mehta RS, Barlow WE, Albain KS, Vandenberg TA, Dakhil SR, et al. Combination anastrozole and fulvestrant in metastatic breast cancer. N Engl J Med. 2012;367:435–44.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Robertson JF, Dixon JM, Sibbering DM, Jahan A, Ellis IO, et al. A randomized trial to assess the biological activity of short-term (pre-surgical) fulvestrant 500 mg plus anastrozole versus fulvestrant 500 mg alone or anastrozole alone on primary breast cancer. Breast Cancer Res. 2013;15:R18.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Martin M, Loibl S, von Minckwitz G, Morales S, Martinez N, et al. Phase III trial evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for advanced breast cancer: the Letrozole/Fulvestrant and Avastin (LEA) study. J Clin Oncol. 2015;33:1045–52.

    Article  CAS  PubMed  Google Scholar 

  19. Turner NC, Ro J, André F, Loi S, Verma S, et al. Palbociclib in hormone-receptor-positive advanced breast cancer. N Engl J Med. 2015;373:209–19.

    Article  CAS  PubMed  Google Scholar 

  20. Baselga J, Im SA, Iwata H, Clemons M, Ito Y, et al. PIK3CA status in circulating tumor DNA predicts efficacy of buparlisib plus fulvestrant in postmenopausal women with endocrine-resistant HR+/HER2− advanced breast cancer: first results from the randomized, Phase III BELLE-2 trial. Program and abstracts of the San Antonio Breast Cancer Symposium (SABCS) S6-01. 2015

  21. Hyams DM, Chan A, de Oliveira C, Snyder R, Vinholes J, et al. Cediranib in combination with fulvestrant in hormone-sensitive metastatic breast cancer: a randomized Phase II study. Invest New Drugs. 2013;31:1345–54.

    Article  CAS  PubMed  Google Scholar 

  22. Robertson JFR, Ferrero J-M, Bourgeois H, Kennecke H, de Boer RH, et al. Ganitumab with either exemestane or fulvestrant for postmenopausal women with advanced, hormone-receptor-positive breast cancer: a randomised, controlled, double-blind, phase 2 trial. Lancet Oncol. 2013;14:228–35.

    Article  CAS  PubMed  Google Scholar 

  23. Clemons MJ, Cochrane B, Pond GR, Califaretti N, Chia SKL, et al. Randomised, phase II, placebo-controlled, trial of fulvestrant plus vandetanib in postmenopausal women with bone only or bone predominant, hormone-receptor-positive metastatic breast cancer (MBC): the OCOG ZAMBONEY study. Breast Cancer Res Treat. 2014;146:153–62.

    Article  CAS  PubMed  Google Scholar 

  24. Zaman K, Winterhalder R, Mamot C, Hasler-Strub U, Rochlitz C, et al. Fulvestrant with or without selumetinib, a MEK 1/2 inhibitor, in breast cancer progressing after aromatase inhibitor therapy: a multicentre randomised placebo-controlled double-blind phase II trial, SAKK 21/08. Eur J Cancer. 2015;51:1212–20.

    Article  CAS  PubMed  Google Scholar 

  25. Krop IE, Mayer IA, Ganju V, Dickler M, Johnston S, et al. Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol. 2016;17:811–21.

    Article  CAS  PubMed  Google Scholar 

  26. Burstein HJ, Cirrincione CT, Barry WT, Chew HK, Tolaney SM, et al. Endocrine therapy with or without inhibition of epidermal growth factor receptor and human epidermal growth factor receptor 2: a randomized, double-blind, placebo-controlled phase III Trial of fulvestrant with or without lapatinib for postmenopausal women with hormone receptor-positive advanced breast cancer—CALGB 40302 (alliance). J Clin Oncol. 2014;32:3959–66.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Cristofanilli M, Turner NC, Bondarenko I, Ro J, Im S-A, et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol. 2016;17:425–39.

    Article  CAS  PubMed  Google Scholar 

  28. Brodie A, Sabnis G. Adaptive changes result in activation of alternate signaling pathways and acquisition of resistance to aromatase inhibitors. Clin Cancer Res. 2011;17:4208–13.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Arpino G, Green SJ, Allred DC, Lew D, Martino S, et al. HER-2 amplification, HER-1 expression, and tamoxifen response in estrogen receptor-positive metastatic breast cancer: a southwest oncology group study. Clin Cancer Res. 2004;10:5670–6.

    Article  CAS  PubMed  Google Scholar 

  30. Lauring J, Park BH, Wolff AC. The phosphoinositide-3-kinase-Akt-mTOR pathway as a therapeutic target in breast cancer. J Natl Compr Canc Netw. 2013;11:670–8.

    CAS  PubMed  PubMed Central  Google Scholar 

  31. Nichols M. New directions for drug-resistant breast cancer: the CDK4/6 inhibitors. Future Med Chem. 2015;7:1473–81.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Miller TW, Hennessy BT, González-Angulo AM, Fox EM, Mills GB, et al. Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer. Clin Invest. 2010;120:2406–13.

    Article  CAS  Google Scholar 

  33. Spoerke JM, Gendreau S, Walter K, Qiu J, Wilson TR, et al. Heterogeneity and clinical significance of ESR1 mutations in ER-positive metastatic breast cancer patients receiving fulvestrant. Nature Commun. 2016;7:11579.

    Article  Google Scholar 

  34. Beaver JA, Amiri-Kordestani L, Charlab R, Chen W, Palmby T, et al. FDA approval: palbociclib for the treatment of postmenopausal patients with estrogen receptor-positive, HER2-negative metastatic breast cancer. Clin Cancer Res. 2015;21:4760–6.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Author notes

    Authors and Affiliations

    1. Department of Medical Oncology, Shantou Central Hospital, Shantou, Guangdong, China

      Wen-Zhao Lin & Xu-Yuan Li

    2. Department of Respiratory Medical Oncology, Cancer Hospital of Shantou University Medical College, Shantou, Guangdong, China

      Qi-Ni Xu & Hong-Biao Wang

    Authors
    1. Wen-Zhao Lin
      View author publications

      You can also search for this author in PubMed Google Scholar

    2. Qi-Ni Xu
      View author publications

      You can also search for this author in PubMed Google Scholar

    3. Hong-Biao Wang
      View author publications

      You can also search for this author in PubMed Google Scholar

    4. Xu-Yuan Li
      View author publications

      You can also search for this author in PubMed Google Scholar

    Corresponding author

    Correspondence to Xu-Yuan Li.

    Ethics declarations

    Conflict of interest

    The authors declared no potential conflicts of interest.

    Additional information

    Wen-Zhao Lin, Qi-Ni Xu, and Hong-Biao Wang contributed equally to this work.

    About this article

    Check for updates. Verify currency and authenticity via CrossMark

    Cite this article

    Lin, WZ., Xu, QN., Wang, HB. et al. Fulvestrant plus targeted agents versus fulvestrant alone for treatment of hormone-receptor positive advanced breast cancer progressed on previous endocrine therapy: a meta-analysis of randomized controlled trials. Breast Cancer 24, 345–352 (2017). https://doi.org/10.1007/s12282-017-0770-3

    Download citation

    • Received:

    • Accepted:

    • Published:

    • Issue Date:

    • DOI: https://doi.org/10.1007/s12282-017-0770-3

    Keywords

    Search

    Navigation